<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04961775</url>
  </required_header>
  <id_info>
    <org_study_id>2020-300-01-EC</org_study_id>
    <nct_id>NCT04961775</nct_id>
  </id_info>
  <brief_title>A Prospective Multi-center Study on Using Sonazoid Diagnose Early Stage Endometrial Cancer</brief_title>
  <official_title>Contrast Enhanced Ultrasound Using Sonazoid Diagnose Early Stage Endometrial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sonazoid as a new generation of ultrasound contrast agent.This study based on the features of&#xD;
      Sonazoid specific angiography and higher mechanical index, the role of Sonazoid in the early&#xD;
      diagnosis of Endometrial carcinoma was explored.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sonazoid is a second generation ultrasound contrast agent, which is composed of microbubbles&#xD;
      containing chemically stable and insoluble Perfluorobutane (PFB) gas and a hard shell of&#xD;
      phosphatidylserine sodium (2-3 μ m in diameter) wrapped in the outer layer. These&#xD;
      microbubbles can generate stable nonlinear oscillations in a low-power acoustic field and&#xD;
      generate echoes at the second harmonic frequency of the transmitted pulse for enhanced&#xD;
      contrast harmonic imaging.&#xD;
&#xD;
      Because Sonazoid has the advantages of ultra long time development and good stability,&#xD;
      Sonazoid has significant clinical advantages in the diagnosis of not focal liver&#xD;
      lesions(FLLs) but breast tumor and other organ. However, there is no study based on contrast&#xD;
      enhanced ultrasound(CEUS) using Sonazoid in early detection of Endometrial carcinoma.&#xD;
      Therefore, based on the advantages of the new ultrasound contrast agent, using qualitative&#xD;
      analysis and quantitative analysis method to collect large samples, compared with diagnosis&#xD;
      results of standard reference, which has important clinical significance for early diagnosis,&#xD;
      early detection and improving the accuracy of diagnosis of Endometrial carcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic performance of contrast-enhanced ultrasound in endometrial cancer by Sonazoid.</measure>
    <time_frame>10 months</time_frame>
    <description>Pathology as a gold standard, to observe the diagnostic performance of Sonazoid in endometrial tumor:a prospective multicenter study based on quantitative and qualitative analysis.</description>
  </primary_outcome>
  <enrollment type="Anticipated">277</enrollment>
  <condition>Endometrial Carcinoma Stage I</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perflubutane Microspheres for Injection</intervention_name>
    <description>16 µL as perflubutane microbubbles (1 vial) is reconstituted with 2 mL of attached water for injection; usually, once for an adult, 0.015 mL/kg as dispersion is administered intravenously.</description>
    <other_name>Sonazoid</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      pathological diagnosis&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with endometrial carcinoma who needs to biopsy or surgical resection;&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1)Patients with Irregular Vaginal bleeding with endometrial thickness is greater than&#xD;
             5mm(Postmenopausal) or10mm (Premenopausal) via transvaginal ultrasound；&#xD;
&#xD;
          -  2)Able to perform curettage or other image examination and surgical pathological&#xD;
             staging；&#xD;
&#xD;
          -  3) Patients with complete clinical data, pathological test and follow-up data；&#xD;
&#xD;
          -  4)Ability to understand, sign informed consent and agree to participate in the&#xD;
             investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1)Patients without Endometrial carcinoma;&#xD;
&#xD;
          -  2)Women during pregnancy and lactation;&#xD;
&#xD;
          -  3)Those who are known to be allergic to ultrasound contrast agents;&#xD;
&#xD;
          -  4)Patients with arterial-venous (right to left) shunt in the heart or lung or with&#xD;
             serious heart diseases or with serious lung diseases;&#xD;
&#xD;
          -  5)Any other condition makes patient not eligible for this clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping Liang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Zhang, Doctor</last_name>
    <phone>13910535695</phone>
    <email>zjbch@vip.sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xin Li, Doctor</last_name>
    <phone>18210198929</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Liang, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>July 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 3, 2021</last_update_submitted>
  <last_update_submitted_qc>July 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Ping Liang</investigator_full_name>
    <investigator_title>Department of Interventional Ultrasound</investigator_title>
  </responsible_party>
  <keyword>Contrast Enhanced Ultrasound</keyword>
  <keyword>Transvaginal ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

